February 15, 2019
Authored and Edited by Katherine T. Leonard; Sydney R. Kestle; Elizabeth D. Ferrill
In Momenta Pharmaceuticals, Inc. v. Bristol-Meyers Squibb Co., No. 17-1694 (Fed. Cir. Feb. 7, 2019), the Federal Circuit dismissed for lack of standing Momenta’s appeal from a final written decision of the Board.
In 2015, Momenta filed a petition for inter partes review of Bristol-Meyers Squibb’s ’239 patent covering its Orencia® product. At that time, Momenta was reportedly attempting to develop a biosimilar counterpart to Orencia®. The Board sustained patentability, and Momenta appealed from that determination.
While Momenta’s appeal was pending, Momenta filed a letter with the Federal Circuit explaining that it would be ceasing its efforts to develop an Orencia® biosimilar. The Court asked Momenta to show cause why its appeal should not be dismissed. Momenta argued that it still retained an economic interest, by way of future royalties, in any development of an Orencia® biosimilar by a third party (Mylan). Soon thereafter, Momenta submitted another letter to the Court explaining it had also ceased its relationship with Mylan.
In light of Momenta’s abandoning development of any Orencia® biosimilar, the Court held that Momenta no longer had a legally protected interest in the validity of the ’239 patent. It likewise found Momenta’s argument that a potential future royalty could confer standing too speculative here. The Court accordingly dismissed Momenta’s appeal for lack of standing.
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Webinar
May 9, 2024
Webinar
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
At the PTAB Blog
USPTO Releases Notice of Proposed Rule Making Codifying Several Precedential Case Factors
April 25, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.